By 2030, will the FDA approve any drug in combination with a checkpoint blockade therapy that substantially reduces immune escape?
GeopolíticaOne-OffSalud y medicina3a
Manifold MarketsSin KYCDatos de resolución verificadosCalibración aceptablePronóstico comunitario actualSí 53.5%
Pronosticadores
5
Tipo de pregunta
binary
Metodología
Play-money forecasting platform
Tipo de fuente
Pronóstico
Datos de mercado
Actualizado hace 23 minutos
18 nov 22, 2:41 UTC1 ene 30, 8:00 UTC
Tendencias
Reglas
Checkpoint blockade therapy (also called immune checkpoint inhibitors) is an cancer therapy that works (roughly speaking) by preventing the cancer from disabling the immune system.
- There's a list of major immune checkpoint inhibitors here: https://en.wikipedia.org/wiki/Checkpoint_inhibitor
- A common issue with this kind of therapy is immune escape: the cancer mutates and escapes from the immune system in some other way, which makes the drug much less effective or even useless.
- You can read an overview of the topic here: https://sci-hub.se/10.1093/annonc/mdw217
- This market resolves YES if any combination therapy is approved that:
- Reduces immune escape by >= 10 percentage points over the course of two years according to any metric in an associated publication.
